Key Market Indicators
Belgium's vaccination coverage for children aged one remains impressively stable. By 2028, the country is projected to maintain its current 98% coverage rate, unchanged from 2023. This consistency has been a hallmark of the Belgian market since 1985. Belgium's vaccine export market is on the rise. The country is expected to see its vaccine exports grow to approximately $7.38 billion by 2028, up from $6.90 billion in 2023. This represents an average annual growth rate of 0.9%. Since 2004, Belgium's vaccine supply has increased by 1.7% year on year. In 2023, Belgium ranked second in vaccine exports, surpassed only by Ireland. The United Kingdom and France trailed behind, securing the third and fourth positions, respectively. On the import front, Belgium's vaccine demand is also increasing. By 2028, the nation's vaccine imports are projected to reach around $8.72 billion, up from $7.51 billion in 2023. This growth translates to a compound annual growth rate (CAGR) of 2.3%. Since 2004, Belgium's vaccine imports have grown by 2.5% annually.
